Loading
Cholangiocarcinoma and Gallbladder Cancer Studies / Colorectal Cancer Treatments and Studies · Journal article
Discover Medicine · August 10, 2026
A consensus or society position rather than new primary data.
This narrative review summarizes the rationale, clinical evidence, and regulatory status of IDH inhibitors in IDH-mutant gliomas and cholangiocarcinoma, noting FDA approvals of ivosidenib and vorasibenib. The review is primarily synthesizing and organizing existing knowledge rather than reporting new empirical data, and identifies resistance mechanisms and future research directions as key challenges.
Narrative review. Patients with IDH-mutant gliomas, cholangiocarcinoma, and colorectal cancer; literature on IDH inhibitors. Intervention: IDH inhibitors (ivosidenib, vorasibenib, and investigational agents).
FDA approved ivosidenib for previously treated metastatic biliary tract cancers FDA approved vorasibenib for IDH mutant low-grade gliomas following surgery Recent clinical studies showed promising data for IDH-targeted therapy in reducing tumor volume
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides clinicians with an organized summary of current IDH-targeted therapeutic options and their FDA status, supporting informed decision-making for IDH-mutant cancers. It also highlights primary and acquired resistance as ongoing challenges requiring further investigation.
A narrative review synthesizing evidence on IDH inhibitors across multiple cancer types, discussing FDA-approved agents, clinical trial data, and resistance mechanisms—informative for clinical decision-making but not reporting original empirical results.
As stated by the source record.
This review provides clinicians with an organized summary of current IDH-targeted therapeutic options and their FDA status, supporting informed decision-making for IDH-mutant cancers. It also highlights primary and acquired resistance as ongoing challenges requiring further investigation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Isocitrate dehydrogenase (IDH) enzyme system plays a central role in cellular metabolism, growth, and differentiation, and its mutations are associated with alterations of the cell cycle and production of oncometabolites, promoting tumor development. In this narrative review, we provide an overview of the current evidence on the therapeutic use of IDH inhibitors in IDH mutant gliomas and gastrointestinal cancers, focusing on cholangiocarcinoma (CCA) and colorectal cancer (CRC). Recent clinical studies showed promising data for IDH-targeted therapy in reducing tumor volume and led to the Food and Drug Administration (FDA) approval of ivosidenib for previously treated metastatic biliary tract cancers and vorasidenib for patients with IDH mutant low-grade gliomas following surgery. In addition, we discuss the emerging, although still limited, evidence regarding IDH mutations in colorectal cancer. Herein, we describe the characteristics of the FDA-approved and other investigational IDH-targeted drugs, evaluating the most recent clinical studies on targeting IDH genomic alterations in the treatment of gliomas and cholangiocarcinoma; we also provide insight into factors involved in resistance to IDH inhibition and potential strategies to overcome resistance mechanisms. Finally, we examine the major challenges facing IDH targeted therapy, including primary and acquired resistance, while highlighting future research directions such as next-generation IDH inhibitors, combination strategies, potential biomarkers, and the integration of molecular profiling into precision oncology to improve clinical outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.